Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» givosiran
givosiran
FDA's rapid review pace nets an early approval for Alnylam's second drug
Biopharma Dive
Wed, 11/20/19 - 10:51 pm
FDA
Alnylam
Givlaari
givosiran
RNAi
porphyria
Alnylam's givosiran reduces mean porphyria attacks by 74% in Phase III
BioCentury
Fri, 04/12/19 - 11:33 pm
Alnylam
FDA
givosiran
acute hepatic porphyria
2 Biotechs With Big Dates in April
Motley Fool
Sat, 03/30/19 - 01:04 pm
Alnylam
EASL
Intercept Pharmaceuticals
Onpattro
givosiran
NASH
Ocaliva
Data in Hand, Alnylam To Seek OK For Second RNAi Drug
Xconomy
Wed, 03/6/19 - 10:07 am
Alnylam
RNAi
FDA
acute hepatic porphyria
givosiran
Upcoming events – Fibrogen and Alnylam look to broaden their horizons
EP Vantage
Sat, 03/2/19 - 12:44 pm
FibroGen
roxadustat
pamrevlumab
Duchenne Muscular Dystrophy
givosiran
Alnylam
Alnylam shares drop 1.8% on new FDA approval strategy for rare disease drug
Marketwatch
Mon, 10/15/18 - 12:05 pm
Alnylam
FDA
givosiran
acute hepatic porphyria
Alnylam, with positive data on second gene-silencing drug, plans filing to FDA
Stat
Thu, 09/27/18 - 10:12 am
Alnylam
gene-silencing
givosiran
FDA
acute hepatic porphyrias
Will 2018 Be Alnylam Pharmaceuticals, Inc.'s Best Year Yet?
Yahoo/Motley Fool
Mon, 01/15/18 - 09:35 am
Alnylam
givosiran
Patisiran
Alnylam lines up Phase 3 for another RNAi drug
BioPharma Dive
Tue, 06/27/17 - 10:33 am
Alnylam
RNAi
givosiran
acute hepatic porphyrias